Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Gross Margin (2020 - 2026)

Journey Medical filings provide 6 years of Gross Margin readings, the most recent being 64.81% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 190.0% to 64.81% in Q4 2025 year-over-year; TTM through Dec 2025 was 65.49%, a 336.0% increase, with the full-year FY2025 number at 65.83%, up 370.0% from a year prior.
  • Gross Margin hit 64.81% in Q4 2025 for Journey Medical, down from 66.2% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 85.27% in Q4 2023 to a low of 41.93% in Q4 2022.
  • Median Gross Margin over the past 5 years was 59.79% (2024), compared with a mean of 58.85%.
  • Biggest five-year swings in Gross Margin: crashed -2318bps in 2021 and later surged 4333bps in 2023.
  • Journey Medical's Gross Margin stood at 45.62% in 2021, then decreased by -8bps to 41.93% in 2022, then skyrocketed by 103bps to 85.27% in 2023, then dropped by -26bps to 62.92% in 2024, then grew by 3bps to 64.81% in 2025.
  • The last three reported values for Gross Margin were 64.81% (Q4 2025), 66.2% (Q3 2025), and 67.09% (Q2 2025) per Business Quant data.